Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEPW) Preferred Stock Liabilities (2021 - 2022)

Coeptis Therapeutics Holdings has reported Preferred Stock Liabilities over the past 2 years, most recently at $33.3 million for Q3 2022.

  • Quarterly results put Preferred Stock Liabilities at $33.3 million for Q3 2022, down 56.09% from a year ago — trailing twelve months through Sep 2022 was $33.3 million (down 56.09% YoY), and the annual figure for FY2021 was $75.8 million, changed.
  • Preferred Stock Liabilities for Q3 2022 was $33.3 million at Coeptis Therapeutics Holdings, up from $33.0 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for COEPW hit a ceiling of $75.8 million in Q4 2021 and a floor of $33.0 million in Q2 2022.